NCT04252586 - A Long-term Safety Study of Cannabidiol Oral Solution (GWP42003-P, CBD-OS) in Patients With Rett Syndrome | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 28, 2020

Primary Completion Date

June 9, 2021

Study Completion Date

June 9, 2021

Conditions

Rett SyndromeRTT

Interventions

DRUG

GWP42003-P

GWP42003-P presented as an oral solution containing cannabidiol in the excipients sesame oil with anhydrous ethanol, sweetener (sucralose), and strawberry flavoring

Trial Locations (31)

10467

Clinical Trial Site, The Bronx

19104

Clinical Trial Site, Philadelphia

21205

Clinical Trial Site, Baltimore

29646

Clinical Trial Site, Greenwood

37232

Clinical Trial Site, Nashville

45229

Clinical Trial Site, Cincinnati

55101

Clinical Trial Site, Saint Paul

60612

Clinical Trial Site, Chicago

77030

Clinical Trial Site, Houston

80045

Clinical Trial Site, Aurora

92093

Clinical Trial Site, La Jolla

35294-0021

Clinical Trial Site, Birmingham

02115

Clinical Trial Site, Boston

63110-1093

Clinical Trial Site, St Louis

Unknown

Clinical Trial Site, Perth

Clinical Trial Site, South Brisbane

Clinical Trial Site, Toronto

Clinical Trial Site, Vancouver

Clinical Trial Site, Genova

Clinical Trial Site, Messina

Clinical Trial Site, Milan

Clinical Trial Site, Rome

Clinical Trial Site, Siena

Clinical Trial Site #1, Barcelona

Clinical Trial Site #2, Barcelona

Clinical Trial Site #1, Madrid

Clinical Trial Site #2, Madrid

Clinical Trial Site, Valencia

Clinical Trial Site, Edinburgh

Clinical Trial Site, Liverpool

Clinical Trial Site, London